GHK-Cu: Published Research, Chemical Identity and Batch Documentation
GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine, which was isolated from human plasma. In fibroblast cultures it stimulated collagen synthesis at nanomolar concentrations, and rat wound-model studies report extracellular-matrix changes alongside at least one null result. Vial & Error supplies GHK-Cu

Batch documentation
The 98%+ purity floor applies to GHK-Cu as it does to every compound we list, and it is verified twice: by the manufacturer COA and by independent analysis at ACS Peptide Testing Labs. The ACS entry for this batch is below.
| Batch tested | Ve2026-chic-001 |
|---|---|
| Laboratory | ACS Peptide Testing Labs |
| Accession number | AAHV643 |
| Purity (LCMS-UV) | 99.94% |
| Mass identification | GHK-Cu |
| Reported | July 28, 2026 |
These numbers are specific to the one sample ACS tested. View the COA and ACS report on the GHK-Cu product page.
What is GHK-Cu? Chemical identity
| Sequence | Gly-His-Lys, copper(II) complex [1] |
|---|---|
| CAS number | 89030-95-5 (prezatide copper) [PubChem] |
| Molecular formula | C14H23CuN6O4+ (as listed by PubChem) [PubChem] |
| Molecular weight | 402.92 g/mol (computed, PubChem) [PubChem] |
| PubChem CID | 71587328 [PubChem] |
Identity values from PubChem CID 71587328. A salt form such as acetate has a higher molecular weight than the value above; defer to the batch COA.
What have published studies on GHK-Cu examined?
About these rows: they include a null result and a finding that did not persist, so they are not a uniform list of positive effects. All are animal or in-vitro experiments, with conditions quoted as published for literature reference only, not as guidance, recommendations or protocols for any use.
| Model type | Model | Concentration or dose (as reported) | Route | Duration | Outcome (as reported) | Source |
|---|---|---|---|---|---|---|
| In vitro | Fibroblast cultures | Effect began at 10⁻¹²–10⁻¹¹ M, maximal at 10⁻⁹ M (as reported) | Culture medium | Not stated in abstract | Increased collagen synthesis, independent of cell number | Maquart FX 1988 [1] PMID 3169264 · DOI |
| Animal | Rat subcutaneous wound chamber | Various concentrations (not stated in abstract) | Injection into wound chamber | Not stated in abstract | Concentration-dependent increases in dry weight, DNA, protein, collagen and glycosaminoglycans; type I and III collagen mRNA up; control tripeptide had no effect | Maquart FX 1993 [2] PMID 8227353 · DOI |
| Animal + in vitro | Rat wound chamber; rat dermal fibroblasts | 2 mg per injection (as reported) | Injection into wound chamber; culture medium | Up to day 22 | Increased type I collagen and glycosaminoglycans; decorin mRNA up and biglycan mRNA down | Siméon A 2000 [3] PMID 11121126 · DOI |
| In vitro | Dermal fibroblast cultures | Not stated in abstract | Culture medium | Not stated in abstract | Increased MMP-2 protein and mRNA, and TIMP-1 and TIMP-2 secretion; copper ions alone reproduced the MMP-2 effect, GHK alone did not | Siméon A 2000 [4] PMID 11045606 · DOI |
| Animal | Rat, ischemic open wounds (n = 24) | 2% gel (as reported) | Topical, daily | 13 days | Wound area reduced 64.5% vs 45.6% (vehicle) and 28.2% (control) by day 13; lower TNF-α, MMP-2 and MMP-9 | Canapp SO Jr 2003 [5] PMID 14648529 · DOI |
| Animal | Rat, ACL reconstruction (n = 72) | 0.3 or 3 mg/mL (as reported) | Intra-articular, weekly from week 2 | 4 weekly injections; assessed at 6 and 12 weeks | Smaller knee-laxity difference and higher stiffness (0.3 mg/mL) at 6 weeks; no differences at 12 weeks; no differences in ultimate load, gait or histology | Fu SC 2015 [6] PMID 25731775 · DOI |
| Animal | Irradiated rat dorsal skin flaps | Not stated in abstract | Topical gel, twice daily | 10 days | No difference vs control in flap ischemia, vessel number or area, or VEGF expression (null result) | Parker NP 2013 [7] PMID 23744835 · DOI |
| In vitro (human-derived cells) | Primary human dermal fibroblasts, normal and irradiated, in culture | 1 × 10⁻⁹ mol/L (as reported) | Serum-free culture medium | Not stated in abstract | Faster population doubling; irradiated cells produced more bFGF and VEGF early after exposure | Pollard JD 2005 [8] PMID 15655171 · DOI |
Anecdotal or calculation only. Not dosing guidance or medical advice. For laboratory research use only.
Every entry draws on the PubMed abstract. A cell marked "Not stated in abstract" means the number sits in the paper’s full text, which we did not transcribe.
What mechanisms have been reported for GHK-Cu?
The first point is background on the peptide; the rest are cell-culture and rat findings from the cited sources, ending with a model where no effect was seen.
- GHK is a tripeptide with an affinity for copper(II) ions that was isolated from human plasma, and a GHK sequence occurs in the α2(I) chain of type I collagen. [1]
- In rat wound chambers and dermal fibroblast cultures, GHK-Cu increased decorin mRNA and decreased biglycan mRNA. [3]
- In fibroblast cultures, GHK-Cu increased MMP-2 expression together with TIMP-1 and TIMP-2 secretion; copper ions alone reproduced the MMP-2 effect but GHK alone did not. [4]
- Not every model shows an effect: in irradiated rat skin flaps, topical GHK-Cu gel produced no difference from control. [7]
Handling and storage of GHK-Cu (supplier guidance)
Supplier guidance pending confirmation: desiccated at −20 °C for the long term and 2–8 °C for the short term, shielded from light and moisture. Bring the vial to room temperature before opening to limit condensation.
No GHK-Cu stability data are cited here, and nothing on this page establishes how long a reconstituted solution remains usable. Defer to your laboratory’s own validated methods.
Why researchers source GHK-Cu from Vial & Error
- A published ACS Peptide Testing Labs report is on file.
- Held to a 98%+ purity floor, with the manufacturer COA and the ACS result both on record.
- The literature table includes studies that found no lasting effect, each linked by PMID or DOI.
Add GHK-Cu to your research order
The GHK-Cu product page holds the COA section for the batch tabulated above, plus ordering.
See GHK-Cu specifications and order Jump to checkout with GHK-Cu
Reading across compounds? The BPC-157 ACS batch report sits on its own page.
Frequently asked questions
What is GHK-Cu?
GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine. PubChem lists prezatide copper (CAS 89030-95-5, CID 71587328) as C14H23CuN6O4+ with a computed molecular weight of 402.92 g/mol.
What models has GHK-Cu been studied in?
The studies in our table used fibroblast cultures (including primary human-derived fibroblasts in vitro) and rat wound, skin-flap and ligament-reconstruction models. Every row is tagged as animal or in vitro.
Do all GHK-Cu studies report an effect?
No. A 2013 irradiated rat skin-flap study found no difference from control, and a 2015 rat ACL study found effects at 6 weeks that were gone by 12 weeks. Both are in our table.
Which GHK-Cu batch was tested by ACS Peptide Testing Labs?
The current ACS Peptide Testing Labs report lists purity by LCMS-UV and mass identification for the sample tested. These numbers are specific to the one sample ACS tested.
How should lyophilized GHK-Cu be stored?
Per supplier guidance (still unconfirmed by manufacturer stability data), keep it desiccated at −20 °C for the long term or 2–8 °C for the short term, away from light and moisture.
Does the GHK-Cu table recommend concentrations?
No. The table records published fibroblast-culture and rat-model conditions as a literature reference, not as guidance for any use. GHK-Cu from Vial & Error is
References
- Maquart FX, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988. PMID 3169264 · doi:10.1016/0014-5793(88)80509-x
- Maquart FX, et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. J Clin Invest. 1993. PMID 8227353 · doi:10.1172/JCI116842
- Siméon A, et al. Expression of glycosaminoglycans and small proteoglycans in wounds: modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu(2+). J Invest Dermatol. 2000. PMID 11121126 · doi:10.1046/j.1523-1747.2000.00166.x
- Siméon A, et al. The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ stimulates matrix metalloproteinase-2 expression by fibroblast cultures. Life Sci. 2000. PMID 11045606 · doi:10.1016/s0024-3205(00)00803-1
- Canapp SO Jr, et al. The effect of topical tripeptide-copper complex on healing of ischemic open wounds. Vet Surg. 2003. PMID 14648529 · doi:10.1111/j.1532-950x.2003.00515.x
- Fu SC, et al. Tripeptide-copper complex GHK-Cu (II) transiently improved healing outcome in a rat model of ACL reconstruction. J Orthop Res. 2015. PMID 25731775 · doi:10.1002/jor.22831
- Parker NP, et al. Effects of topical copper tripeptide complex on wound healing in an irradiated rat model. Otolaryngol Head Neck Surg. 2013. PMID 23744835 · doi:10.1177/0194599813492644
- Pollard JD, et al. Effects of copper tripeptide on the growth and expression of growth factors by normal and irradiated fibroblasts. Arch Facial Plast Surg. 2005. PMID 15655171 · doi:10.1001/archfaci.7.1.27
[PubChem] National Center for Biotechnology Information. PubChem Compound Summary, CID 71587328.